Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Henlius BiotechFRA:2E8 -2.67%50 PB Ratio is 8.26 as of Aug. 16, 2026, which is 70% above its 10-year median of 4.86. GuruFocus rates FRA:2E8 with a GF Score™ of 50/100 and a GF Value™ of €3.38 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,220 Biotechnology companies, Shanghai Henlius Biotech ranks worse than 82.7% on this metric.
The historical rank and industry rank for Shanghai Henlius Biotech's PB Ratio or its related term are showing as below:
FRA:2E8'
s PB Ratio Range Over the Past 10 Years
Min: 2.01 Med: 4.86 Max: 14.12
Current: 8.36
During the past 9 years, Shanghai Henlius Biotech's highest PB Ratio was 14.12. The lowest was 2.01. And the median was 4.86.
FRA:2E8's PB Ratio is ranked worse than 82.7% of 1220
companies
in the Biotechnology industry
Industry Median: 2.88
vs FRA:2E8: 8.36
During the past 12 months, Shanghai Henlius Biotech's average Book Value Per Share Growth Rate was 36.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 33.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.10% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Shanghai Henlius Biotech was 33.80% per year. The lowest was -25.70% per year. And the median was 4.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Shanghai Henlius Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Henlius Biotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai Henlius Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Shanghai Henlius Biotech (FRA:2E8) has a PB Ratio of 8.26 as of Aug. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Henlius Biotech and its competitors. This is 70% above median its historical median of 4.86. Over the past decade, Shanghai Henlius Biotech's PB Ratio has ranged from 2.01 to 14.12. According to the industry distribution chart, Shanghai Henlius Biotech ranks #1009 out of 1220 companies in the Biotechnology industry, placing it in the top 82.7%.
Is Shanghai Henlius Biotech's PB Ratio too high?
Shanghai Henlius Biotech's current PB Ratio of 8.26 is 70% above median its 10-year median of 4.86. Over the past 10 years, this metric has ranged from a low of 2.01 to a high of 14.12. The Biotechnology industry median PB Ratio is 2.88. Shanghai Henlius Biotech's value of 8.26 is 186.8% above this industry median. Based on the distribution chart, Shanghai Henlius Biotech ranks #1009 out of 1220 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Henlius Biotech has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Henlius Biotech ranks #1009 out of 1220 companies for PB Ratio. This places Shanghai Henlius Biotech in the lower half of its industry. The industry median PB Ratio is 2.88. Shanghai Henlius Biotech's value of 8.26 is 186.8% above this benchmark. Historically, Shanghai Henlius Biotech's own PB Ratio has ranged from 2.01 to 14.12 over the past decade. While the company's 10-year median is 4.86 vs. the industry median of 2.88, Shanghai Henlius Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.88, based on 1,220 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Henlius Biotech's current PB Ratio of 8.26 is 186.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Henlius Biotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Henlius Biotech's current PB Ratio is 8.26, which is 70% above median its own 10-year median of 4.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (FRA:2E8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.38, compared to a current price of €7.30 — trading 116% above its estimated fair value. The current PB Ratio is 8.26, which is 70% above median its 10-year median of 4.86 and 186.8% above the Biotechnology industry median of 2.88. Shanghai Henlius Biotech's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Shanghai Henlius Biotech (FRA:2E8), the current PB Ratio is 8.26 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Henlius Biotech (FRA:2E8) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued.
The current stock price of €7.30 is trading 116% above its estimated GF Value™ of €3.38.
GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.
Key valuation signals for FRA:2E8:
PB Ratio: 8.26 (70% above median its 10-year median of 4.86)
GF Value™: €3.38 vs. price of €7.30 (116% above fair value)
Industry Position: 186.8% above the Biotechnology median (#1009 of 1220)
No single metric tells the full story. See the FRA:2E8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
50GF Score
Get the complete analysis for FRA:2E8
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E8 has been successfully added to your 
